Inclusion Criteria:  Group A: A prospective group of up to 20 patients will be included in this cohort. All patients will undergo initial diagnostic workup, staging, and treatment per the institution standard of care. All patients will be discussed at multidisciplinary tumor board and considered eligible for HDBRT treatment provided they are not amenable to treatment with local ablative therapies or transarterial therapies such as TACE and y90. Patients with liver lesions must be over the age of 18 and meet at least one criterion from both sections one and two outlined below.  Any patient with up to five unresectable tumors that are:  At least 3cm (largest diameter in the axial plane). In close proximity to large blood vessels. In close proximity to sensitive structures (bowel, stomach, diaphragm, liver capsule, liver hilum, bile ducts). Associated with difficult endovascular access to one or more feeding arterial branches (hypovascular tumors). Associated with a large shunt fraction to other vital organs.  Exclusion criteria:  Active infectious disease Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, interstitial lung disease, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Patients with polymetastatic disease with the exception of those patients who may benefit from therapy addressing local complications directly related to the target lesion diminishing quality of life such as pain, vascular/biliary occlusion, and liver disfunction. Pregnancy (Sexually active patients must be on birth control while participating in this study). Child-Pugh class C Total serum bilirubin > 2 mg/dl Platelet count < 50,000/ul INR > 1.5